Dermatomycosis Market: Current Analysis and Forecast (2024-2032)

The dermatomycosis market globally refers to the diagnosis, treatment, and mitigation of fungal skin diseases brought by dermatophytes, yeasts, and molds. Some of the factors that are acting as drivers to this market include the growing incidence rate of chronic diseases such as diabetes and immunocompromising diseases that render the patient more prone to acquire fungal infections, skin health, and cleanliness awareness. New developments in antifungal drugs, a rise in global healthcare spending, and growth in the healthcare sector in developing economies also continue to contribute to market growth. Furthermore, continuous research and development of new products promising better treatments and increasing demand for over-the-counter antifungal medicines contribute to the highly dynamic dermatomycosis market, regionally and internationally.

The market for dermatomycosis is set to exhibit a growth rate of about 4%. This is mainly due to the increasing prevalence of fungal infections globally and advancements in diagnostic techniques for fungal infections driving the growth of the market. For instance, In December 2023, Astellas Pharma announced the U.S. FDA approval of CRESEMBA, an azole antifungal drug for treating invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients. This FDA approval helped the company to diversify its product portfolio and boost its revenue.

Based on the drugs, the market is segmented into corticosteroids, corticosteroid-sparing agents, immunosuppressive, immunomodulator, antifungals, and others. The corticosteroids segment should display the highest CAGR of the dermatomycosis market as it increases the effectiveness and efficiency of antifungal agents and controls the inflammation and itching sensations of fungal disease. In the therapy of mycoses, corticosteroids are further combined with antifungal agents, thus decreasing symptoms and enhancing patient compliance, ultimately resulting in improved therapy outcomes. Given the fact that they facilitate the regulation of severe inflammation in dermatomycosis patients, they are easily recognized as an indispensable part of multimodal therapeutic strategies. Thus, looking for corticosteroids in preparing dermatomycosis cures increases market demand and further development of new efficient combined treatments.

Based on the route of administration, the market is segmented into oral, parenteral, topical, and others. Among these, the parenteral category is expected to grow at the fastest CAGR due to offering direct and often more potent delivery of antifungal medications. This method consists of using parenteral solutions, including the intravenous administration of medications through injections or infusions, which is important in treating the more dangerous forms of dermatomycosis or where topical and oral treatments do not suffice. Parenteral administration is preferred by hospitals and other specialized healthcare facilities due to the high bioavailability of a substance in the bloodstream making it suited for use in seriously ill patients. In addition, factors enhancing the demand for systemic antifungal agents include the increased prevalence of immunocompromising diseases worldwide coupled with a higher risk of developing severe fungal infections besides requiring parenteral administration and hospitalization.

Based on the end-user, the market is segmented into hospitals, specialty clinics, and others. Among these, the hospitals category is expected to grow at the fastest CAGR because hospitals are providing a wide range of antifungal therapies, including topical creams, oral medications, and parenteral treatments, tailored to the severity and type of fungal infection. Furthermore, hospitals serve as hubs for clinical research and trials, fostering innovation in antifungal treatments and therapies. Their role in educating healthcare professionals and patients about prevention, diagnosis, and treatment options also enhances market awareness and drives demand for effective dermatomycosis management strategies.

For a better understanding of the market adoption of dermatomycosis, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America accounts for the major share during the forecast period. This is mainly due to the increasing incidences of diabetes, rising awareness about skin health, and a robust healthcare infrastructure. The region benefits from advanced medical research and a strong presence of key pharmaceutical companies that are continuously developing new and effective antifungal treatments. The high demand for both prescription and over-the-counter antifungal products is supported by well-established distribution channels, including retail pharmacies and online platforms. Additionally, the focus on innovation and the adoption of advanced technologies for diagnosis and treatment enhance the market's growth prospects. Public health campaigns and educational initiatives aimed at improving hygiene and early detection of skin infections also contribute to the expanding market.

Some of the major players operating in the market include Pfizer Inc.; AstraZeneca; Eli Lilly and Company; GALDERMA LABORATORIES, L.P.; Hikma Pharmaceuticals PLC; Novartis AG; Johnson & Johnson Services, Inc.; Astellas Pharma US, Inc.; Mylan N.V.; Taro Pharmaceutical Industries Ltd.